person · Reporting owner
Ciongoli Gregory Austin
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director · 10% owner · See Remarks | June 09, 2026 | June 11, 2026 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | September 23, 2026 | September 25, 2026 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | August 25, 2026 | August 27, 2026 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,000 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 12,000 · Balance 12,000 F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,209,395 |
Reported balance
Holding disclosure · report date 2026-06-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,209,395 F2: The securities reported on this row are directly held by Adiumentum Capital Fund I LP, a limited partnership organized under the laws of Delaware ("Adiumentum"). Adiumentum Capital Fund I GP LLC, a limited liability company organized under the laws of Delaware ("Adiumentum GP"), is the general partner of Adiumentum. Gregory A. Ciongoli is the managing partner of Adiumentum and the managing member of Adiumentum GP. Each of Adiumentum, Adiumentum GP, and Mr. Ciongoli may be deemed to have the shared power to vote or direct the vote (and the shared power to dispose or direct the disposition of) the securities that are directly held by Adiumentum. Each of Adiumentum, Adiumentum GP, and Mr. Ciongoli may be deemed to have a pecuniary interest in the securities that are directly held by Adiumentum, but disclaims any beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
F2: The securities reported on this row are directly held by Adiumentum Capital Fund I LP, a limited partnership organized under the laws of Delaware ("Adiumentum"). Adiumentum Capital Fund I GP LLC, a limited liability company organized under the laws of Delaware ("Adiumentum GP"), is the general partner of Adiumentum. Gregory A. Ciongoli is the managing partner of Adiumentum and the managing member of Adiumentum GP. Each of Adiumentum, Adiumentum GP, and Mr. Ciongoli may be deemed to have the shared power to vote or direct the vote (and the shared power to dispose or direct the disposition of) the securities that are directly held by Adiumentum. Each of Adiumentum, Adiumentum GP, and Mr. Ciongoli may be deemed to have a pecuniary interest in the securities that are directly held by Adiumentum, but disclaims any beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Gossamer Bio, Inc.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.99 · Expires 2036-09-22 | Direct | 30,000 |
Reported balance
After 2026-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 30,000 · Balance 30,000 F1: 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date.
REGENXBIO Inc.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 118,035 |
Ending reported balance
After 2026-08-27 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Grant · Acquired 15,432 · Balance 15,432 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 1/3rd of the shares subject to the RSU award shall vest on each of August 25, 2027, August 25, 2028 and August 25, 2029, while the recipient provides continuous service to the Issuer. Row 2 · 2026-08-26 · Purchase · Acquired 49,196 · Balance 64,628 F2: Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $8.67 to $9.35. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-08-27 · Purchase · Acquired 53,407 · Balance 118,035 F3: Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $9.17 to $9.4525. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91 · Expires 2036-08-25 | Direct | 69,609 |
Reported balance
After 2026-08-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-25 · Grant · Acquired 69,609 · Balance 69,609 F4: The option will vest over a three year period, with 1/3rd of the option vesting on August 25, 2027 and the remaining portion of the option vesting in equal monthly installments over the 24 months thereafter, while the optionee provides continuous service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 1/3rd of the shares subject to the RSU award shall vest on each of August 25, 2027, August 25, 2028 and August 25, 2029, while the recipient provides continuous service to the Issuer.
F2: Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $8.67 to $9.35. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $9.17 to $9.4525. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: The option will vest over a three year period, with 1/3rd of the option vesting on August 25, 2027 and the remaining portion of the option vesting in equal monthly installments over the 24 months thereafter, while the optionee provides continuous service to the Issuer.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 21:01 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001628280-26-063616 · wk-form4_1790370069.xml · derivative · entry 1 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-09-22 F1 · derivative.exercise_date: 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
| August 27, 2026 Filed Aug 27, 2026 23:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | PurchaseCommon Stock | 53,407 | $9.36 | $499,675.89 |
DisclosureSEC source: 0002023732-26-000008 · primarydocument.xml · nonDerivative · entry 3 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,035 F3 · price: Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $9.17 to $9.4525. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 23:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | PurchaseCommon Stock | 49,196 | $9.14 | $449,705.56 |
DisclosureSEC source: 0002023732-26-000008 · primarydocument.xml · nonDerivative · entry 2 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,628 F2 · price: Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $8.67 to $9.35. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 23:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 69,609 | $0.00 Strike: $8.91 | $0.00 |
DisclosureSEC source: 0002023732-26-000008 · primarydocument.xml · derivative · entry 4 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,609 Underlying: Common Stock · 69,609 shares Expires 2036-08-25 F4 · derivative.exercise_date: The option will vest over a three year period, with 1/3rd of the option vesting on August 25, 2027 and the remaining portion of the option vesting in equal monthly installments over the 24 months thereafter, while the optionee provides continuous service to the Issuer. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 23:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 15,432 | $0.00 | $0.00 |
DisclosureSEC source: 0002023732-26-000008 · primarydocument.xml · nonDerivative · entry 1 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,432 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 1/3rd of the shares subject to the RSU award shall vest on each of August 25, 2027, August 25, 2028 and August 25, 2029, while the recipient provides continuous service to the Issuer. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002919 · form4.xml · nonDerivative · entry 1 Ciongoli Gregory Austin · CIK 0002023732 · Director · 10% owner · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 F1 · shares: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:59 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010864 · ownership.xml · derivative · entry 2 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:59 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010864 · ownership.xml · derivative · entry 1 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 00:30 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantCommon Stock | 415,000 | $12.02 | $4,988,300.00 |
DisclosureSEC source: 0000950170-25-107544 · ownership.xml · nonDerivative · entry 1 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,500 Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 00:30 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0000950170-25-107544 · ownership.xml · derivative · entry 3 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2035-08-10 F2 · derivative.exercise_date: Stock options vest in 36 equal monthly installments starting one month after grant date of August 11, 2025. Read SEC document |
| May 16, 2025 Filed May 16, 2025 22:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantWarrants (right to buy) · Derivative | 227,000 | $6.61 Strike: $0.00 | $1,500,447.30 |
DisclosureSEC source: 0001104659-25-050116 · tm2515303-1_4seq1.xml · derivative · entry 2 Adiumentum Capital Fund I LP · CIK 0002023734 · Director · 10% owner · See remarks Adiumentum Capital Fund I GP LLC · CIK 0002023736 · Director · 10% owner · See remarks Ciongoli Gregory Austin · CIK 0002023732 · Director · 10% owner · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,193 Underlying: Common Stock · Not disclosed shares Expires not disclosed F3 · derivative.exercise_date: The warrants are immediately exercisable and do not expire. F3 · derivative.expiration_date: The warrants are immediately exercisable and do not expire. F4 · derivative.underlying_shares: Pursuant to the terms of the warrants, the Issuer may not effect any exercise of any warrant, and a holder of a warrant does not have the right to exercise any portion of the warrant held by such holder, to the extent that, after giving effect to the attempted exercise set forth in a notice of exercise, such holder, together with such holder's affiliates and any other person whose beneficial ownership of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer would be aggregated with such holder's for the purposes of Section 13(d) of the Exchange Act, and the applicable regulations of the U.S. Securities and Exchange Commission (the "SEC"), including any "group" of which such holder is a member, would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation. F5 · derivative.underlying_shares: The "Beneficial Ownership Limitation" is 19.99% of the shares of Common Stock then issued and outstanding, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. F4 · balance_after: Pursuant to the terms of the warrants, the Issuer may not effect any exercise of any warrant, and a holder of a warrant does not have the right to exercise any portion of the warrant held by such holder, to the extent that, after giving effect to the attempted exercise set forth in a notice of exercise, such holder, together with such holder's affiliates and any other person whose beneficial ownership of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer would be aggregated with such holder's for the purposes of Section 13(d) of the Exchange Act, and the applicable regulations of the U.S. Securities and Exchange Commission (the "SEC"), including any "group" of which such holder is a member, would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation. F5 · balance_after: The "Beneficial Ownership Limitation" is 19.99% of the shares of Common Stock then issued and outstanding, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. F1 · ownership.direct: In addition to Adiumentum Capital Fund I LP, a limited partnership organized under the laws of Delaware ("Adiumentum"), this Form 4 is being filed jointly by Adiumentum Capital Fund I GP LLC, a limited liability company organized under the laws of Delaware and the general partner of Adiumentum ("Adiumentum GP"), and Gregory A. Ciongoli, a citizen of the United States of America and the managing member of Adiumentum GP (together with Adiumentum and Adiumentum GP, the "Reporting Persons"). Each of the Reporting Persons has the same business address as Adiumentum and may be deemed to have a pecuniary interest in securities reported on this Form 4 (the "Subject Securities"). Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein. F2 · ownership.direct: Adiumentum may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Securities. Adiumentum GP, as the general partner of Adiumentum may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Securities. Mr. Ciongoli, as the managing partner of Adiumentum, and as the managing member of Adiumentum GP, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Securities. Read SEC document |
| May 16, 2025 Filed May 16, 2025 22:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 75,572 | $6.61 | $499,530.92 |
DisclosureSEC source: 0001104659-25-050116 · tm2515303-1_4seq1.xml · nonDerivative · entry 1 Adiumentum Capital Fund I LP · CIK 0002023734 · Director · 10% owner · See remarks Adiumentum Capital Fund I GP LLC · CIK 0002023736 · Director · 10% owner · See remarks Ciongoli Gregory Austin · CIK 0002023732 · Director · 10% owner · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,209,395 F1 · ownership.direct: In addition to Adiumentum Capital Fund I LP, a limited partnership organized under the laws of Delaware ("Adiumentum"), this Form 4 is being filed jointly by Adiumentum Capital Fund I GP LLC, a limited liability company organized under the laws of Delaware and the general partner of Adiumentum ("Adiumentum GP"), and Gregory A. Ciongoli, a citizen of the United States of America and the managing member of Adiumentum GP (together with Adiumentum and Adiumentum GP, the "Reporting Persons"). Each of the Reporting Persons has the same business address as Adiumentum and may be deemed to have a pecuniary interest in securities reported on this Form 4 (the "Subject Securities"). Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein. F2 · ownership.direct: Adiumentum may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Securities. Adiumentum GP, as the general partner of Adiumentum may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Securities. Mr. Ciongoli, as the managing partner of Adiumentum, and as the managing member of Adiumentum GP, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.